Clinical Research Directory
Browse clinical research sites, groups, and studies.
Outcomes of NeoMTA and NeoPUTTY Pulpotomies in Primary Molars
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
The goal of this clinical trial is to evaluate the outcomes of different medications used for pulpotomies (baby root canal) in children. The main question it aims to answer is: • what are the long-term clinical and radiographic success of pulpotomies in baby teeth using two different medications (NeoMTA and NeoPUTTY) over a 24-month follow-up period? Healthy children aged between 3 and 10 years undergoing dental treatment under general anesthesia who have deep caries lesions approximating or reaching the nerve will be invited to participate in this study. Pulpotomies (baby root canal) will be performed by trained dentists following a protocol. Children will receive pulpotomies either with NeoMTA or NeoPUTTY, two medications indicated for the procedure. Participants will be asked to come for an appointment at 1, 6, 12 and 24 months after the procedure. Researcher will compare the clinical and radiographic performance of pulpotomies (baby root canal) done with both medications.
Official title: Clinical and Radiographic Outcomes of NeoMTA and NeoPUTTY Pulpotomies in Primary Molars: A Randomized Controlled Trial
Key Details
Gender
All
Age Range
3 Years - 10 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2024-04
Completion Date
2027-03
Last Updated
2024-04-23
Healthy Volunteers
Yes
Conditions
Interventions
Primary molars pulpotomies with NeoMTA
Primary molar pulpotomies will be performed by trained dentists using NeoMTA, a bioactive material containing calcium silicate known for its bio-active and bone forming potential. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes
Primary molar pulpotomies with NeoPUTTY
Primary molar pulpotomies will be performed by trained dentists using NeoPUTTY, a ready to use bioactive material containing calcium silicate. Follow-up visits at 1, 6, 12 and 24 months will be conducted to assess success rate, and clinical and radiographic outcomes